• Dominique Valteau-Couanet, Véronique Minard-Colin, and Claudia Pasqualini.
• Département de Cancérologie de l'enfant et de l'adolescent, Gustave Roussy, 94800 Villejuif, France.
• Med Sci (Paris). 2019 Dec 1; 35 (12): 997-1000.

AbstractNeuroblastoma is the most frequent extra-cranial pediatric solid tumor, occurring in young children, 90% being less than 5 years at diagnosis. It remains a therapeutic challenge since survival of high-risk neuroblastoma patients that represent around 50% of the patients is around 50% in spite of extensive combined treatments. Immunotherapy based on the use of antibodies directed to GD2, a ganglioside strongly expressed by almost all neuroblastoma cells, has been developed during the last decade. In SIOPEN studies have shown that dinatuximab beta (Qarziba®) is effective on refractory/relapsed patients and improves survival when administered in the first line maintenance treatment. Other strategies are currently explored using combination with chemotherapy at relapse and evaluating the benefits of an earlier administration during the induction treatment. In addition, more selective antibodies are also developed to decrease toxicity, especially neuropathic pain that is one of the major toxic effect.© 2019 médecine/sciences – Inserm.

25 keywords...

hide…